BRIGHT MINDS BIOSCIENCES INC.
For the period ended Mar 31, 2026. Filed May 20, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Mar 31, 2026 · Filed May 20, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · Overall Analysis
Overall Analysis
The Company incurred net and comprehensive loss of $10,459,627 and $18,024,945 for the three months and six months ended March 31, 2026 compared to a net loss of $2,950,385 and $2,900,775 for the comparable periods. The increase in net loss was primarily attributable to a significant increase in research and development expenditures as the Company expanded its clinical and development activities during the period, as well as higher consulting fees, professional costs, and regulatory expenses incurred to support these initiatives. In addition, the period reflected an increase in stock-based compensation, principally within directors' compensation, compared to the prior year. These increases were partially offset by higher interest income earned on increased cash balances during the quarter.
BRIGHT MINDS BIOSCIENCES INC. MANAGEMENT'S DISCUSSION AND ANALYSIS FOR THE SECOND QUARTER ENDED MARCH 31, 2026 (All amounts expressed in Canadian dollars, unless otherwise stated)
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.